1999
Detoxification of Methylglyoxal by the Nucleophilic Bidentate, Phenylacylthiazolium Bromide
Ferguson G, VanPatten S, Bucala R, Al-Abed Y. Detoxification of Methylglyoxal by the Nucleophilic Bidentate, Phenylacylthiazolium Bromide. Chemical Research In Toxicology 1999, 12: 617-622. PMID: 10409401, DOI: 10.1021/tx990007y.Peer-Reviewed Original ResearchConceptsEscherichia coli double mutantRapid cell deathE. coli cellsDetoxification of methylglyoxalExponential-phase cellsDouble mutantSensitive bacterial assayColi cellsCell deathPhase cellsE. coliLong-term complicationsPotassium channelsReactive dicarbonylsBacterial assaysDetoxificationEndogenous nucleophilesCellsMethylglyoxalTissue damage
1998
Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit
Panagiotopoulos S, O'Brien R, Bucala R, Cooper M, Jerums G. Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. Atherosclerosis 1998, 136: 125-131. PMID: 9544739, DOI: 10.1016/s0021-9150(97)00192-5.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation endproductsAortic archAbdominal aortaAdvanced glycationPlaque formationVasculopathy of diabetesAnti-atherogenic effectsHigh-cholesterol dietCholesterol-fed rabbitsDevelopment of atherosclerosisDegree of atheromaCholesterol dietAortaAtheromaRabbitsThoracicAminoguanidineDosesGlycationTreatmentArchAge levelsNon-enzymatic interactionVasculopathySudan IV
1997
Efficient Scavenging of Fatty Acid Oxidation Products by Aminoguanidine
Al-Abed Y, Bucala R. Efficient Scavenging of Fatty Acid Oxidation Products by Aminoguanidine. Chemical Research In Toxicology 1997, 10: 875-879. PMID: 9282836, DOI: 10.1021/tx970035l.Peer-Reviewed Original ResearchConceptsLow-density lipoprotein levelsAdvanced glycation end productsGlycation end productsMechanism of actionVascular wall componentsLipoprotein levelsLipoprotein metabolismOxidative stressPharmacological inhibitorsFatty acid oxidation productsHuman subjectsToxic effectsAminoguanidineOxidative damageNormal pathwayReactive aldehydesRecent studiesPotential interactionsDamaging effectsVivoTissue constituentsEnd productsAtherogenesisLipid oxidationMalondialdehyde
1996
Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment
Soulis T, Cooper M, Vranes D, Bucala R, Jerums G. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney International 1996, 50: 627-634. PMID: 8840295, DOI: 10.1038/ki.1996.358.Peer-Reviewed Original ResearchConceptsRenal advanced glycation end productsAdvanced glycation end productsExperimental diabetic nephropathyDiabetic nephropathyEffect of aminoguanidineDiabetic ratsAminoguanidine treatmentMesangial expansionStudy periodAccumulation of AGEsUrinary albumin excretionTiming of therapyDevelopment of albuminuriaWeeks of treatmentDuration of treatmentGlycation end productsTiming of treatmentPresence of aminoguanidineAminoguanidine administrationAminoguanidine therapyAlbumin excretionRenoprotective effectsTissue fluorescenceExperimental diabetesLate administrationWhat is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine?
Bucala R. What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine? Diabetes Research And Clinical Practice 1996, 30: s123-s130. PMID: 8964186, DOI: 10.1016/s0168-8227(96)80048-9.Peer-Reviewed Original ResearchConceptsDiabetic patientsLDL levelsEndothelium-derived relaxing factorsElevated LDL levelsEffects of hyperglycemiaLow-density lipoproteinRelaxing factorsVascular diseaseVascular pathologyVascular permeabilityNormal controlsClinical observationsAdvanced glycosylationLipoprotein depositionVascular wallELISA techniqueClearance mechanismsNitric oxideClearance kineticsPatientsELISA analysisLDLAgeAminoguanidineLipoprotein
1995
Advanced Glycosylation Endproducts in Diabetic Renal Disease: Clinical Measurement, Pathophysiological Significance, and Prospects for Pharmacological Inhibition
Bucala R, Vlassara H. Advanced Glycosylation Endproducts in Diabetic Renal Disease: Clinical Measurement, Pathophysiological Significance, and Prospects for Pharmacological Inhibition. Blood Purification 1995, 13: 160-170. PMID: 7619388, DOI: 10.1159/000170199.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation endproductsDiabetic renal diseaseNormal renal functionInactivate nitric oxideSpecific therapeutic modalitiesTissue LDL receptorsForms of LDLRenal functionRenal diseaseLDL levelsTherapeutic modalitiesVascular permeabilityPathophysiological significanceAdvanced glycosylationLipoprotein depositionPharmacological inhibitionLDL receptorClinical measurementsNitric oxideEndothelial cellsMarked increaseMiddle moleculesLDLToxic effectsEndproducts
1992
Hemoglobin-AGE: A Circulating Marker of Advanced Glycosylation
Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R. Hemoglobin-AGE: A Circulating Marker of Advanced Glycosylation. Science 1992, 258: 651-653. PMID: 1411574, DOI: 10.1126/science.1411574.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation end productsAdvanced glycosylationAGE-modified formAGE-specific antibodiesComplications of agingDiabetes-induced hyperglycemiaAge-related complicationsGlycosylation end productsCirculating MarkersDiabetic patientsRenal diseaseGlucose-derived Amadori productsNormal individualsComplicationsPatientsTissue modificationsTissue proteinsHemoglobinAmadori productsEnd productsPercentDiabeticsHyperglycemiaAtherosclerosisDiabetes